BCDA — BioCardia, Inc.

Summary of BioCardia (BCDA) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Research and Development (R&D) Expenses: Increased to $936,000 for Q3 2025 from $931,000 in Q3 2024; year-to-date R&D expenses rose to $3.8 million from $3.0 million.
• Selling, General, and Administrative (SG&A) Expenses: Decreased to $600,000 in Q3 2025 from $800,000 in Q3 2024; year-to-date SG&A expenses fell to $2.4 million from $2.8 million.
• Net Loss: Reported at $1.5 million for Q3 2025, down from $1.7 million in Q3 2024; year-to-date net loss increased to $6.2 million from $5.5 million.
• Cash Position: Ended Q3 2025 with $5.3 million in cash, bolstered by a $6 million financing and share sales under the ATM program. Cash is expected to fund operations into 2026 without the need for additional financing.

2. Strategic Updates and Business Highlights

• Clinical Programs: Progressing with the CardiAmp autologous cell therapy for ischemic heart failure, receiving FDA breakthrough designation. Active enrollment in the confirmatory Phase III CardiAmp Heart Failure II trial is underway.
• Regulatory Engagements: Positive preliminary consultations with Japan's PMDA regarding the CardiAmp system, with expectations for further discussions to facilitate market entry in Japan.
• Helix Delivery System: Updates to the Helix system have been completed, and a de novo submission for FDA approval is anticipated in Q4 2025.
• Partnerships: Collaboration with CAR TECH for Heart 3D Fusion Imaging is progressing, with plans to advance to clinical trials in 2026.

3. Forward Guidance and Outlook

• Clinical Milestones: Anticipate PMDA clinical review in Japan and FDA meeting request in Q4 2025. A manuscript for publication regarding the CardiAmp Heart Failure II trial is expected in Q1 2026.
• Funding Expectations: Non-dilutive funding for the CARDI allo allogeneic mesenchymal stem cell therapy (BCDA03) is anticipated in 2026, with high probability of support from NIH.

4. Challenges and Points of Concern

• Increased R&D Costs: Continued investment in clinical trials may lead to higher R&D expenses in the near term.
• Enrollment Challenges: While enrollment in the CardiAmp Heart Failure II trial is progressing, bandwidth and resource constraints are noted as potential hurdles.
• Regulatory Uncertainties: The need for successful consultations with Japanese regulatory authorities poses a risk to timely market entry.
• Market Competition: The company faces competition in the cell therapy space, particularly in the context of regulatory approvals and clinical outcomes.

5. Notable Q&A Insights

• Patient Enrollment: Management indicated that enrollment for the CardiAmp Heart Failure II trial is smoother due to improved patient selection criteria, but resource limitations are a concern.
• Data Presentation: Clarification was provided regarding the incremental data from the cardiac CMI study, emphasizing the compelling nature of the results despite being based on a small cohort.
• Funding Discussions: Management expressed optimism about securing federal grant funding for BCDA03, highlighting ongoing discussions with the NIH as a potential source of support.

This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, and challenges faced by BioCardia as discussed in the Q3 2025 earnings call.